Not just your wife, emotional relationships with siblings, friends, neighbours and co-workers can also result in lower testosterone levels as you age, researchers including an Indian-origin scientist report.
November 2015
.gif)
The U.S. Food and Drug Administration approved Cotellic (cobimetinib) to be used in combination with vemurafenib to treat advanced melanoma that has spread to other parts of the body or can’t be removed by surgery, and that has a certain type of abnormal gene (BRAF V600E or V600K mutation).
(adsbygoogle = window.adsbygoogle || []).push({});
DS Biopharma, a biopharmaceutical company, announced that its patent covering the use of bioactive active pharmaceutical ingredient (API) DS102 (15-HEPE) for fatty liver disorders has been granted by the European Patent Office (EPO).
Five years after the introduction of MenAfriVac, an affordable vaccine for meningitis A produced by Indian firm Serum Institute of India, immunization has led to the near elimination of the deadly disease in Africa's 'meningitis belt', says the Clinical Infectious Diseases journal.
Abcam, a supplier of life science research tools, is to acquire AxioMx, an American antibody technology firm, for US$25m. The firm, based in Cambridge, UK has agreed the deal and will pay $20m to AxioMx with further performance payments of up to $5m over five years. The deal is expected to be completed by the end of this month.
The French firm presented its plan for the production of a universal flu vaccine at the World Vaccines Congress in Madrid. The company supplied over 220 million doses of seasonal influenza vaccines in 2014.
Olivier Charmeil, president and chief executive of Sanofi Pasteur says: "As the world's leader in the production of influenza vaccines, Sanofi Pasteur's ambition is to drive innovation and to shape the future by exploring several of the leading influenza vaccine strategies."
At the World Vaccine Congress, Dr Harry Kleanthous, Sanofi Pasteur’s associate vice president for research, discussed the potential for broader-spectrum flu vaccine approaches. This he said could lead to the development of a vaccine that stimulates protection against many influenza strains, unlike the current licensed vaccines that are designed to protect against three of four strains and often need to be changed every year, as dominant flu vaccine strains change and new strains emerge.
Kleanthous says: "We are actively exploring the development of a more-broadly protective influenza vaccine that will be designed to prevent the seasonal mismatches that can occur and that are not addressed using the current technology.
“They are complementary but can be considered 'tailored' antigens, in that they are designed to re-focus the immune response to key protective epitopes on the hemagglutinin, which is the active component of our currently licensed influenza vaccines," he continued. "These antigens are still a key player in any flu vaccine, since antibodies directed against them are responsible for preventing the flu virus from binding to and infecting the cell. Creating new antigens is a central theme in our strategy."
Sanofi Pasteur has an existing R&D collaboration agreement with the University of Georgia on a method that – according to Dr Kleanthous – could yield a novel, synthetic vaccine based on the hemagglutinin protein, designed to protect against seasonal influenza strains spanning several years, including strains not yet in existence.
Their experimental vaccine is a novel synthetic vaccine generated from key genetic sequences of many flu viruses, and is termed ‘computationally optimized broadly reactive antigen’ or COBRA, and is designed to protect against many strains over several years, due to the common sequences many flu viruses share.
Meanwhile London-based PepTCell, trading as SEEK, has also made moves in the manufacturing and production of a universal flu vaccine. SEEK has joined a collaboration with the US National Institute of Allergy and Infectious Diseases (NIAID), to jointly lead a study of SEEK’s universal flu candidate, FLU-v.
The trial will assess the safety and immunogenicity of a cross-seasonal universal flu candidate. In a ‘challenge’ trial where patients are first provided with the trial medication and then ‘challenged’ with a known pathogen.
Flu kills between 250,000 to 500,000 people globally every year. The annual vaccine has to be recreated and approved each year as the new season’s influenza virus strains emerge.
Subscribe to PharmaTutor News Alerts by Email >>
Roche announced the launch of the VENTANA HE 600 system, the latest fully automated hematoxylin and eosin (H&E) tissue staining system that enhances patient and technician safety and produces exceptional staining quality.
The VENTANA HE 600 system delivers fresh reagents on each individual slide without relying on user-supplied alcohol and deionized (DI) water, resulting in improved consistency and quality in tissue staining. This individual slide staining technology mitigates the risk of specimen cross contamination that can occur with other technologies, helping to reduce patient misdiagnosis.
AstraZeneca, along with its global biologics research and development arm, MedImmune, will present positive data today from the Phase II trial of anifrolumab for the treatment of moderate-to-severe systemic lupus erythematosus (SLE or lupus) at the American College of Rheumatology (ACR) 2015 Annual Scientific Meeting in San Francisco.
Astellas Pharma Inc. and Ocata Therapeutics, Inc., a biotechnology company focused on the research and development of new therapies in the field of regenerative medicine, primarily cell therapy addressing unmet medical needs in ophthalmology patients, announced that they have entered into a definitive agreement. Under the agreement, Astellas will acquire Ocata through Laurel Acquisition Inc., a wholly-owned subsidiary of Astellas US Holding, Inc. ("Laurel").
Medical experts said High Frequency Ultrasound can be used as a better diagnostic tool for investigating bone and joint problems which are not detected by other existing tests like computed tomography (CT) scan and magnetic resonance imaging (MRI) scan. Musculoskeletal (MSK) Ultrasound, a high frequency ultrasound, can give accurate diagnosis and can be done on pregnant women, children and elderly people, Dr Nidhi Bhatnagar, a specialist radiologist, said here at a press conference organised by Musculoskeletal Ultrasound Group, an association of radiologists and orthopaedic surgeons.
RECOMMENDED POSTS
Subscribe with us
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
Also Join: 
.png)
